Aquestive Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Aquestive Therapeutics, Inc. (AQST) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-11
- Aquestive Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $216.00K, a 64.00% decline year-over-year.
- Aquestive Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$2.80M.
- Aquestive Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $5.09M, a 455.68% increase year-over-year.
- Aquestive Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $118.00K.
- Aquestive Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $3.03M.
- Aquestive Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$1.49M.
- Aquestive Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$2.52M.
- Aquestive Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$2.38M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $216.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.59M 10-Q · filed 2026-08-11 | $2.50M derived: sum of 3 quarters · filed 2026-08-11 | $2.62M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$2.80M 10-Q · filed 2026-05-13 | $2.29M derived: sum of 2 quarters · filed 2026-05-13 | $2.40M derived: sum of 3 quarters · filed 2026-05-13 | $3.00M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $5.21M derived: sum of 2 quarters · filed 2026-03-04 | $5.81M derived: sum of 3 quarters · filed 2026-08-11 | $3.03M 10-K · filed 2026-03-04 | |
| 2025-09-30 | $118.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $718.00K derived: sum of 2 quarters · filed 2026-08-11 | -$2.06M 10-Q · filed 2025-11-05 | -$1.14M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$2.18M 10-Q · filed 2026-08-11 | -$1.26M derived: sum of 3 quarters · filed 2026-08-11 | -$1.92M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$2.78M 10-Q · filed 2026-05-13 | -$1.86M derived: sum of 2 quarters · filed 2026-05-13 | -$2.52M derived: sum of 3 quarters · filed 2026-05-13 | -$2.40M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $916.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $254.00K derived: sum of 2 quarters · filed 2026-03-04 | $381.00K derived: sum of 3 quarters · filed 2026-03-04 | -$1.49M 10-K · filed 2026-03-04 | |
| 2024-09-30 | -$662.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$535.00K derived: sum of 2 quarters · filed 2025-11-05 | -$2.41M 10-Q · filed 2025-11-05 | -$1.45M derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-06-30 | $127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$1.75M 10-Q · filed 2025-08-11 | -$792.00K derived: sum of 3 quarters · filed 2025-08-11 | $382.00K derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$1.87M 10-Q · filed 2025-05-12 | -$919.00K derived: sum of 2 quarters · filed 2025-05-12 | $255.00K derived: sum of 3 quarters · filed 2025-05-12 | -$916.00K derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $954.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $2.13M derived: sum of 2 quarters · filed 2025-03-05 | $957.00K derived: sum of 3 quarters · filed 2025-03-05 | -$2.52M 10-K · filed 2025-03-05 | |
| 2023-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $3.00K derived: sum of 2 quarters · filed 2024-11-04 | -$3.47M 10-Q · filed 2024-11-04 | -$3.49M derived: sum of 4 quarters · filed 2024-11-04 | |
| 2023-06-30 | -$1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$4.64M 10-Q · filed 2024-08-06 | -$4.67M derived: sum of 3 quarters · filed 2024-08-06 | -$5.00M derived: sum of 4 quarters · filed 2024-08-06 | |
| 2023-03-31 | -$3.47M 10-Q · filed 2024-05-07 | -$3.50M derived: sum of 2 quarters · filed 2024-05-07 | -$3.83M derived: sum of 3 quarters · filed 2024-05-07 | -$1.89M derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$361.00K derived: sum of 2 quarters · filed 2024-03-05 | $1.58M derived: sum of 3 quarters · filed 2024-03-05 | -$2.38M 10-K · filed 2024-03-05 | -$2.35M 10-K · filed 2023-03-31 |
| 2022-09-30 | -$336.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.61M derived: sum of 2 quarters · filed 2023-11-06 | -$2.36M 10-Q · filed 2023-11-06 | -$1.16M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | $1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$2.02M 10-Q · filed 2023-08-07 | -$819.00K derived: sum of 3 quarters · filed 2023-08-07 | $106.00K derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$3.96M 10-Q · filed 2023-05-02 | -$2.76M derived: sum of 2 quarters · filed 2023-05-02 | -$1.84M derived: sum of 3 quarters · filed 2023-05-02 | -$2.31M derived: sum of 4 quarters · filed 2023-05-02 | |
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.13M derived: sum of 2 quarters · filed 2023-03-31 | $1.66M derived: sum of 3 quarters · filed 2023-03-31 | -$844.00K 10-K · filed 2023-03-31 | |
| 2021-09-30 | $925.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $455.00K derived: sum of 2 quarters · filed 2022-11-01 | -$2.05M 10-Q · filed 2022-11-01 | $318.00K derived: sum of 4 quarters · filed 2022-11-01 | |
| 2021-06-30 | -$470.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$2.97M 10-Q · filed 2022-08-02 | -$607.00K derived: sum of 3 quarters · filed 2022-08-02 | $858.00K derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | -$2.50M 10-Q · filed 2022-05-04 | -$137.00K derived: sum of 2 quarters · filed 2022-05-04 | $1.33M derived: sum of 3 quarters · filed 2022-05-04 | $2.15M derived: sum of 4 quarters · filed 2022-05-04 | |
| 2020-12-31 | $2.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $3.83M derived: sum of 2 quarters · filed 2022-03-08 | $4.65M derived: sum of 3 quarters · filed 2022-03-08 | $2.98M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $1.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $2.28M derived: sum of 2 quarters · filed 2021-11-02 | $616.00K 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $818.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$849.00K 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | -$1.67M 10-Q · filed 2021-05-04 | ||||
| 2019-12-31 | $746.00K 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |